Crossmark

Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study

Crossref DOI link: https://doi.org/10.1007/s11523-019-00691-z

Published Online: 2019-12-09

Published Print: 2020-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Seung Tae

Hong, Jung Yong

Lee, Jeeyun

Park, Joon Oh

Lim, Ho Young

Kang, Won Ki

Park, Young Suk
License Information

Text and Data Mining valid from 2019-12-09

Version of Record valid from 2019-12-09
More Information

Article History

First Online: 9 December 2019

Compliance with ethical standards

:

: No external funding was used in the preparation of this article.

: Seung Tae Kim, Jung Yong Hong, Jeeyun Lee, Joon Oh Park, Ho Young Lim, Won Ki Kang, and Young Suk Park declare that they have no conflicts of interest that might be relevant to the contents of this article.

Document is current

Any future updates will be listed below